FLGT Looks Ready To Bring Big Return FLGT 看来会带来大利润

Fulgent Genetics, Inc., (FLGT 12.80) together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves Hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally.

。Great Q3 earning report:
. Record billable tests of 20,697, growing 272% year over year
. Record revenue of $10.3 million, growing 84% year over year
. Gross Margin improves 8.9 percentage points year over year and 5.4 percentage points sequentially; cost per test improves 60% year over year and 15% sequentially
. GAAP income of $1.5 million, or $0.08 per share
. Non-GAAP income of $2.6 million, or $0.14 per share
. Cash flow from operations of positive $3.9 million
. Adjusted EBITDA of $3.0 million

。Next year estimated EPS growth is 205%，estimated next 5 year EPS growth is 32%

。Healthy financial situation：0 debt， Current ratio 12

。Small share float and can easily get push up：only 5.97 million shares

。Increasing institution ownership: Institution own 10% of stock, a 3 month increase of 39%

。Pipper Jaffrey upgrade FLGT from Neutral to Overweight

。Technical: FLGT's big 36% percentage up move today on 8.8 times average volume is indicative of great momentum. It formed a break away gap and is breaking out to all time high after a 2.5 months correction on up trend.  On the weekly chart it formed a Bullish Engulfing pattern and looks ready for the second leg up. Based on Measured Move calculation, its next target is around 16. Supports are 12.4 to 12.85 then 11.

Fulgent Genetics，Inc.（FLGT 12.80）及其子公司提供具有临床可行诊断信息给医生的基因检测服务。其技术平台汇集了数据比较和抑制算法，自适应学习软件，遗传诊断工具以及集成的实验室流程。该公司主要服务医院和医疗机构。它通过内部销售人员以及在美国，加拿大，中华人民共和国和国际上的独立销售代表来销售其测试产品。

。出色的第三季度收益报告：
.创记录的计费测试20,697次，同比增长272％
.收入达到创纪录的1,030万美元，同比增长84％
.毛利率同比提高8.9个百分点，比上一季度提高5.4个百分点；每次测试的费用同比提高60％，比上季度提高15％
. GAAP收入为150万美元，或每股0.08美元
.非GAAP收入为260万美元，或每股0.14美元
.运营现金流为390万美元
.调整后的EBITDA为300万美元

。明年估计每股收益增长205％，估计未来5年每股收益增长32％。

。健康的财务状况：债务为0，流动比率为12

。流通量少，可轻易被推高：只有597万股

。机构持股增加：机构拥有10％的股份，三个月内增加了39％

。PiperJaffray将FLGT评级从中性升级到超重

。技术面：今天，FLGT的交易量达到了平均水平的8.8倍，股价涨幅高达36％，预示着强劲的发展势头。在上涨趋势中经过2.5个月的修正后，今天它形成了一个突破性缺口，并突破到历史最高点。在周线图上，它形成了看涨吞没模式，看来准备并开始第二波上升。以“Measured Move”计算，他的下一个目标约为16。支撑12.4-12.85之间然后11。